JANX - Janux Therapeutics GAAP EPS of -$0.41 revenue of $2.37M
- Janux Therapeutics press release ( NASDAQ: JANX ): Q2 GAAP EPS of -$0.41.
- Collaboration Revenue of $2.37M.
- The company had $354.3 million in cash and cash equivalents and short-term investments at end of second quarter 2022
For further details see:
Janux Therapeutics GAAP EPS of -$0.41, revenue of $2.37M